NO976112L - 1,6-disubstituted isochromes for the treatment of migraine - Google Patents

1,6-disubstituted isochromes for the treatment of migraine

Info

Publication number
NO976112L
NO976112L NO976112A NO976112A NO976112L NO 976112 L NO976112 L NO 976112L NO 976112 A NO976112 A NO 976112A NO 976112 A NO976112 A NO 976112A NO 976112 L NO976112 L NO 976112L
Authority
NO
Norway
Prior art keywords
treatment
isochromes
disubstituted
migraine
useful
Prior art date
Application number
NO976112A
Other languages
Norwegian (no)
Other versions
NO976112D0 (en
Inventor
Michael D Ennis
Ruth E Tenbrink
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO976112D0 publication Critical patent/NO976112D0/en
Publication of NO976112L publication Critical patent/NO976112L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår 1,6-disubstituerte isokromaner av formel (I) og aromatiske, bisykliske aminer (ABA) som er anvendbare for behandling av hodepine, spesielt migrene og klase- hodepine, og også anvendbare som anti- psykotiske midler og for behandling av andre CNS og/eller kardiovaskulære syk- dommer, og som analgetiske midler.The present invention relates to 1,6-disubstituted isochromes of formula (I) and aromatic bicyclic amines (ABA) which are useful for the treatment of headaches, in particular migraine and cluster headaches, and also useful as antipsychotics and for the treatment of other CNS and / or cardiovascular diseases, and as analgesic agents.

NO976112A 1995-06-30 1997-12-29 1,6-disubstituted isochromes for the treatment of migraine NO976112L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74195P 1995-06-30 1995-06-30
US1123496P 1996-02-06 1996-02-06
PCT/US1996/008681 WO1997002259A1 (en) 1995-06-30 1996-06-07 1,6-disubstituted isochromans for treatment of migraine headaches

Publications (2)

Publication Number Publication Date
NO976112D0 NO976112D0 (en) 1997-12-29
NO976112L true NO976112L (en) 1998-03-02

Family

ID=26668092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO976112A NO976112L (en) 1995-06-30 1997-12-29 1,6-disubstituted isochromes for the treatment of migraine

Country Status (12)

Country Link
EP (1) EP0836599A1 (en)
JP (1) JPH11509532A (en)
AU (1) AU6252296A (en)
BR (1) BR9609631A (en)
CA (1) CA2225282A1 (en)
CZ (1) CZ418597A3 (en)
FI (1) FI974640A (en)
MX (1) MX9710260A (en)
NO (1) NO976112L (en)
PL (1) PL324319A1 (en)
SK (1) SK164297A3 (en)
WO (1) WO1997002259A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2370270A (en) * 2000-12-20 2002-06-26 Lilly Co Eli Pharmaceutical compounds
US7335660B2 (en) 2001-12-19 2008-02-26 Eli Lilly And Company Isochroman compounds for treatment of CNS disorders
GB0130339D0 (en) * 2001-12-19 2002-02-06 Lilly Co Eli Isochroman compounds
US7110576B2 (en) 2002-12-30 2006-09-19 Pitney Bowes Inc. System and method for authenticating a mailpiece sender
AU2005238179B2 (en) 2004-05-05 2010-08-26 F. Hoffmann-La Roche Ag Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
RU2389723C2 (en) 2004-12-21 2010-05-20 Ф. Хоффманн-Ля Рош Аг Tetraline and indane derivatives and use thereof
CA2592001A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and their use as 5-ht receptor ligands
RU2396255C2 (en) 2004-12-21 2010-08-10 Ф. Хоффманн-Ля Рош Аг Tetraline and indan derivatives and application thereof
ES2314749T3 (en) 2004-12-21 2009-03-16 F. Hoffmann-La Roche Ag DERIVATIVES OF TETRALINA AND INDANO AND USES OF THE SAME AS 5-HT ANTAGONISTS.
CA2591810A1 (en) 2004-12-21 2006-06-29 F.Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
ES2359735T3 (en) 2005-11-03 2011-05-26 F. Hoffmann-La Roche Ag ARYLSULPHONYL CHROMANES AS 5-HT6 INHIBITORS.
BRPI0713742A2 (en) 2006-06-20 2013-02-13 Hoffmann La Roche arylsulfonyl naphthalene derivatives and uses of these
AU2007263084A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
CN101472883A (en) 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 Arylsulfonamidyl tetralin derivatives and uses thereof
US20110313197A1 (en) * 2009-03-05 2011-12-22 Sumitomo Chemical Company, Limited Method for producing halogen-substituted benzene dimethanol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552004A (en) * 1976-05-26 1979-09-05 Takeda Chemical Industries Ltd Isochroman derivatives
NZ277373A (en) * 1993-12-28 1998-07-28 Upjohn Co Iso(thio)chroman-1-ylethylpiperazine and -piperidine derivatives (analogues)

Also Published As

Publication number Publication date
FI974640A0 (en) 1997-12-30
MX9710260A (en) 1998-03-29
BR9609631A (en) 1999-03-02
FI974640A (en) 1997-12-30
CA2225282A1 (en) 1997-01-23
EP0836599A1 (en) 1998-04-22
AU6252296A (en) 1997-02-05
JPH11509532A (en) 1999-08-24
SK164297A3 (en) 1998-09-09
PL324319A1 (en) 1998-05-25
CZ418597A3 (en) 1998-06-17
WO1997002259A1 (en) 1997-01-23
NO976112D0 (en) 1997-12-29

Similar Documents

Publication Publication Date Title
NO976112L (en) 1,6-disubstituted isochromes for the treatment of migraine
YU64092A (en) FLUORALCOXIBENZAMINO DERIVATIVES OF HETEROCYCLIC UNITS CONTAINING NITROGEN
FI941022A (en) Spirocyclic piperidine derivatives
FI931370A (en) QUANTITATIVE ANALOGER AV ICKE-AROMATIC HETEROCYCLISM FOERENINGAR MED EN FUSIONERAD RING
MX9702865A (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-idoles as estrogenic agents.
ATE263157T1 (en) NEMATICIDE TRIFLUORBUTENE
MD1838G2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
DK0772604T3 (en) Trialzole compounds and their use as dopamine D3 ligands
NO20006645L (en) New form of irbesartan, process for obtaining said form and pharmaceutical preparations containing the same
DK0934309T3 (en) Novel pyridylalkanoic acid amides as cytostatic and immunosuppressive agents
ATE202776T1 (en) PIPERINE DERIVATIVES AS NEUROKININ ANTAGONISTS
DK0737189T3 (en) Heterocyclic Compounds for the Treatment of CNS Disorders and Cardiovascular Disorders
DE69530988T2 (en) BENZIMIDAZOLE DERIVATIVES WITH DOPAMINERIC EFFECT
IS6914A (en) 2-thio-substituted imidazole derivatives and their use in the pharmaceutical industry
BR0113461A (en) Pharmaceutically acceptable compounds or salts, pharmaceutical compositions, method of treating erab, hadh2 or (beta) -amyloid-mediated disease or condition in mammals, methods of inhibiting or modulating erab or hadh2 enzymatic activity, and method of treating alzheimer's disease or dementia in mammals
YU22802A (en) Isonipectoamides for the treatment of integrinmediates disorders
CO5150221A1 (en) NEW 3-PHENOXI- AND 3-PHENYLALQUILOXI-2-PHENYL-SUBSTITUTED PROPILAMINS
HUP0001118A2 (en) N-substituted pyrrolidine derivatives, process for preparing the same and pharmaceutical compositions containing them
DE59406501D1 (en) SUBSTITUTED IMINOACETONITRILE WITH MYOCARD PROTECTIVE EFFECT
NO970498L (en) Benzimidazole derivatives with dopaminergic activity
MX9704733A (en) 4,4-(disubstituted)cyclohexan-1-one monomers and related compounds.